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Abstract Personalised treatment of heart disease requires an
understanding of the patient-specific characteristics, which
can vary over time. A newly developed implantable surface
acoustic wave pressure sensor, capable of continuous moni-
toring of the left ventricle filling pressure, is a novel device for
personalised management of patients with heart disease.
However, a one-size-fits-all approach to device sizing will
affect its positioning within the pulmonary artery and its rela-
tionship to the interrogating device on the chest wall on a
patient-specific level. In this paper, we analyse the spatial
orientation and morphology of the pulmonary artery and its
main branches in patients who could benefit from the device
and normal controls. The results could optimise the design of
the sensor, its stent, and importantly its placement, ensuring
long-term monitoring in patient groups.
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monitoring . Orientation .Morphology
Abbreviations
PA Pulmonary artery
RPA Right pulmonary artery
LPA Left pulmonary artery
LV Left ventricle
HF Heart failure
HFpEF Heart failure with a preserved ejection fraction
NYHA New York Heart Association
ID Interrogating device
BSA Body surface area
SAWPS Surface acoustic wave pressure sensor
FEM Finite element modelling
CT Computed tomography
MR Magnetic resonance
PS Pulmonary sinuses
Introduction
Heart failure is one of the leading causes of morbidity and
mortality worldwide [1–4]. The disease is generally progres-
sive, with the advanced forms of the disease carrying a very
poor prognosis, and importantly, it is becoming more resistant
to conventional therapy [5, 6]. Therapy is based on a combi-
nation of pharmaceutical agents, any of which can have side-
effects which should be avoided. Therapy must therefore be
personalised, taking into account patient-specific
haemodynamics which can also vary over time. A principal
control variable would ideally be pulmonary blood pressure as
it usually reflects left ventricular filling pressures. Monitoring
progression is therefore essential for improving outcome.
Changes in filling pressures of the left ventricle (LV) have
been shown to precede symptoms, making accurate measure-
ments of these pressures both at rest and exercise a priority in
managing these patients [7, 8].
Several implantable devices have been developed to mon-
itor LV filling pressures noninvasively, either indirectly or
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directly [9–13]. The EndoSure device (CardioMems, St. Jude
Medical, St Paul, MN, USA) [9, 10] can only be interrogated
at intervals, as the recording system requires the patient to lie
down, providing only a snapshot of information at rest. This is
a major limitation as some patients show normal resting
haemodynamics but with pathological elevation in LV filling
pressures during exercise [14, 15]. This is most pertinent for
patients with heart failure with a preserved ejection fraction
(HFpEF) as well as patients with primary pulmonary hyper-
tension (PH).
The only device which can provide continuous monitoring
of the filling pressure at rest and during exercise is the im-
plantable surface acoustic wave pressure sensor (SAWPS)
[16] currently is being developed at Imperial College
London. The sensor is designed with an antenna that is
mounted on a nitinol stent to be placed in the patient’s pulmo-
nary artery (PA). The accuracy and reliability of the measure-
ment critically depends on the position of the sensor in the
pulmonary artery and its relationship to the interrogating de-
vice (ID) on the chest wall. Accurate characterization of the
various morphologies of the PA and its branches, as well as its
relation to the chest wall, therefore, is critical to the develop-
ment and placement of the monitoring device.
The goal of this study is to analyse spatial orientation and
morphology across different patient populations. While stud-
ies on the measurements of the PA diameter at the level of the
bifurcation have been performed [17], the examination of how
the diameter and orientation changes across the PA length has
not been considered. Additionally, choosing the ideal location
of the ID on the chest wall to improve signal and reading is
addressed in detail. We studied the PAs of 25 individuals (20
candidates with heart failure or pulmonary arterial hyperten-
sion and 5 normal controls) and performed initial experiments
in virtual stent fitting and preclinical deployment.
Methods
SAWPS Device
The surface acoustic wave pressure sensor (SAWPS) is a nov-
el wireless transponder used in conjunction with a miniature
communication system for continuous evaluation of PA pres-
sure in patients with severe heart failure and those with pul-
monary hypertension. It allows for accurate measurements to
be taken on a continuous basis, and then transmitted remotely,
allowing for blood pressure to be continuously monitored
throughout waking and sleeping activities [18]. The implant-
able SAWPS components are an antenna and a passive,
battery-less sensor fixed on an expandable Nitinol stent as
shown in Fig. 1. When implanted, accurate PA pressure mea-
surements from the sensor are transferred to an external inter-
rogation system, which on the one hand powers the sensor and
on the other hand receives, interprets, retransmits, and stores
the acquired signal.
Previous studies by Murphy et al. [16, 18] were conducted
to specify design, material properties and mechanical charac-
teristics of the sensor, antenna and interrogator/transmitter to
assure sufficient wave propagation and signal transfer. The
antenna is designed to have a suitable shape and the required
radiation efficiency for use in the PA and the length of the
antenna from tip to tip is currently set to 37 mm.
Additionally, finite element modelling (FEM) and experi-
ments were conducted to identify arterial stress patterns and
stent radial forces for different stent strut thickness [4].
Study Population
The study includes normal subjects and a representative sam-
ple of the patients who could potentially benefit from the
SAWPS device (Table 1). 15 heart failure (HF) patients,
grouped according to the New York Heart Association
(NYHA) classes [19] (5 NYHA Class II, 5 NYHA Class III
and 5 NYHA Class IV), who were admitted in the Aswan
Heart Centre (AHC) Heart Failure Clinic, and 5 patients with
pulmonary hypertension (groups 1 and 4) underwent clinical
investigation. 5 healthy subjects were included in the normal
cohort. The average age and body surface area (BSA) for each
group were: 58±11/1.83±0.21 m2 for NYHA Class II pa-
tients, 51 ± 8/1.86 ± 0.20 m2 for NYHA Class III, 62 ± 10/
2.07±0.25 m2 for NYHA Class IV and 30±5/1.84±0.37 m2
for PH and 32±3/1.92±0.05 m2 for normal subjects.
For each patient, images of the PA and chest wall structure
were acquired. Selected heart failure and pulmonary hyperten-
sion patients had archived computed tomography (CT) im-
ages, scanned using a dual-source 128-slice FLASH
Siemens CT scanner. The acquisition for heart failure patients
followed a breath-hold, cardiac-gated scanning protocol with
a slice thickness of 0.6 mm. Pulmonary hypertension patients
Fig. 1 The surface acoustic wave sensor (SAWPS)
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had breath-hold, non-gated CT scans with a slice thickness of
1 mm. For the controls, gated scans were used.
All subjects’ data utilised in this study were based on data
previously acquired for clinical purposes after approval from
the Ethics Committee.
3D Analysis—Spatial Orientation and Morphology
To determine the range of PA sizes and orientations the
SAWPS device must accommodate, 3D analysis of the PA
was performed to extract the necessary parameters to ensure
that the final device(s) will fit in the majority of patients. The
workflow is shown in Fig. 2.
The DICOM images were imported into Mimics
(Materialise, Leuven, Belgium) for segmentation of the PA
(including left and right pulmonary arteries) and the chest
wall. The models of the structures were then exported as tri-
angular meshes in STL format. In addition, the centrelines of
the PA models were automatically produced by Mimics and
exported. The STL models were imported into MeshLab [20]
to remove noise in the meshes through the use of Poisson
mesh regeneration; these final meshes were exported for final
measurements and analysis in MATLAB.
The proximal section of the PAwas divided into two main
segments. The first was the main pulmonary artery (MPA)
leading to the left pulmonary artery (LPA), as shown in
Table 2. The second was the right pulmonary artery (RPA),
treated as a branch off the first structure. Along the length of
the MPA-LPA centrelines, four main landmarks were manu-
ally identified: the pulmonary valve, the beginning of the RPA
branch off the MPA, the end of the RPA branch off the MPA,
and the first branch of the LPA. The analysis of the MPA-LPA
was from the pulmonary valve to the first branch of the LPA.
The analysis of the RPAwas from the branch off the MPA and
terminated at its first branch.
To attempt to normalise PA centreline lengths, the
centreline for each MPA-LPA structure was linearly interpo-
lated and the MPA and LPAwere sampled to 50 points each,
both separated by the bifurcation that leads to the RPA.
Likewise, the centreline for each RPA structure was linearly
interpolated and sampled to 40 points, with the number of
points chosen empirically. These points were ordered and
the lengths along the PA segments (as described in Table 2)
Table 1 Clinical data of the
subjects included in this study Group Gender Age Weight (kg) Height (cm) BSA (m
2)
HF NYHA Class II F 69 63 154 1.64
M 61 88 173 2.05
M 65 60 168 1.67
M 55 85 180 2.06
F 42 65 171 1.75
HF NYHA Class III M 43 89 168 2.04
F 62 61 158 1.64
F 53 75 170 1.88
F 55 64 157 1.67
M 43 93 168 2.08
HF NYHA Class IV F 61 90 160 2.00
F 78 66 152 166
M 63 97 180 2.20
M 58 110 170 2.28
M 50 105 170 2.23
PH M 26 131 170 2.49
F 28 74 155 1.78
F 28 65 156 1.68
F 39 69 156 1.73
F 29 54 157 1.53
Normal M 33 79 177 1.97
M 27 80 172 1.96
M 43 75 176 1.91
F 35 73 170 1.86
F 29 77 166 1.88
HF heart failure, NYHA New York Heart Association functional classification, PH pulmonary hypertension
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were calculated as the lengths of their corresponding
centrelines. The vector was defined by the line segments⇀
PiPiþ1, where Pi is the ith point in the centreline, was used
as the normal to the ith orthogonal cutting plane. There was
one orthogonal cutting plane for each point in the centrelines.
For each centreline point, the intersections of the cutting
plane with the surface mesh of the PAwere calculated and the
resulting line segments were ordered into a contour. The area
of each contour corresponded to the cross sectional area of the
PA. A circle was also fitted to the points in this contour [21]
Fig. 2 Processing flowchart for medical imaging derived 3D analysis of PA
Table 2 Parameters and segments of the PA for personalised SAW device design optimization
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and the diameter of this circle was used as the approximation
of the diameter of the PA. For each centreline point, the min-
imum Euclidean distance from the point to the chest wall was
recorded; likewise, the closest point on the chest wall was
recorded.
Finally, to examine the orientation of the different parts of
the PAwith respect to each other, vectors were defined along
the lengths of the beginning of the RPA branch, the end of the
MPA, and the beginning of the LPA. The angles between these
vectors were also recorded as parameters.
Statistical analysis of the parameters was also performed in
MATLAB. The data was expressed as mean and standard
deviation across patient groups and PA segments. The
Kruskall-Wallis test was used to compare the various param-
eters across the multiple groups. Statistical significance was
indicated by p values below 0.05.
Virtual Deployment
With the measurements, stent sizes for the patient groups were
proposed. Virtual deployment was performed by aligning the
resized stent mesh file within an example patient PA to check
for suitability.
Results
Statistical analysis of the basic data of the study population
(Table 1) showed statistically significant differences
(p = 0.001) for the ages of the different patient cohorts.
Height and weight of patients from the groups were not sta-
tistically significant (p>0.1).
In Fig. 3, the average lengths of the PA centrelines of all
subject groups are shown. In all subjects, the average length of
the MPA was generally less than 20 mm, shorter than the
current length of the SAWPS device stent. This suggests that
the stent will need to be shorter than this or long enough to
straddle the RPA bifurcation and be fixed in both theMPA and
LPA. The average lengths of this bifurcation were 26.0
± 9.5 mm for Class 2, 21.5 ± 3.1 mm for Class 3, 20.5
± 3.2 mm for Class 4, 22.4 ± 3.0 mm for PH, and 16.5
±3.4 mm for Controls. The average lengths of the LPAwere
31.8±13.3 mm for Class 2, 30.3±8.6 mm for Class 3, 35.1
± 3.4 mm for Class 4, 33.3 ± 8.7 mm for PH, and 25.3
±4.7 mm for Controls. For completeness, the average RPA
length was also calculated. These were 45.8±22.6 mm for
Class 2, 37.0±6.2 mm for Class 3, 44.0±5.7 mm for Class
4, 34.9 ± 4.8 mm for PH, and 34.9 ± 3.1 mm for Controls.
When examined separately, only the lengths of the MPAwere
found to be statistically significant (p=0.02). However, when
examining the entire length of the MPA through to the LPA
(Fig. 3b), this entire length was also statistically significant
(p=0.01).
Figure 3 also shows the average height of the pulmonary
sinuses and the average minimum distances from the PA to the
chest wall. The average heights were 15.6±2.6 mm for Class
2, 12.7±1.7 mm for Class 3, 15.2±2.1 mm for Class 4, 14.9
±1.3 mm for PH, and 14.6±2.5 mm for Controls. The average
minimum distances from the PA to the chest wall were 54.9
± 14.2 mm for Class 2, 59.1 ± 8.9 mm for Class 3, 68.1
± 11.9 mm for Class 4, 63.6 ± 14.1 mm for PH, and 61.1
±8.2 mm for Controls. Both measurements were found to be
statistically insignificant across patient groups (p>0.05).
Figure 4 highlights the differences in the average cross
sectional areas and diameters across the MPA, LPA and RPA
of different patient cohorts. The top row shows the average
cross sectional area of the PA lumen contour normalised to
patient height (cm2/m) while the bottom row shows the aver-
age diameters of the same contours. The general trend over the
average is greater cross sectional area and diameters for the
PH group and lower parameters for the Controls. The average
diameter from the MPA to the LPA, i.e. after the bifurcation,
lowers by approximately 6 mm, indicating that the stent, if it is
to straddle the bifurcation, needs to be flexible enough to
adapt to the two diameters.
From Table 2, four landmarks can be seen marked on the
PA on the left hand side: the start and end of the MPA, and the
start and end of the LPA. When examining the cross sectional
areas and diameters at these landmark points, statistical sig-
nificance was found at the start and end of the MPA and the
end of the LPA (p<0.05). No statistical significance was
found at the start of the LPA across the patient groups.
These measurements will affect the diameter required of the
stent.
Figure 5 shows one example of the distances of the skin
surface from the MPA and LPA (a patient from NYHA Class
2). The graphs across all subjects resembled this, where the
minimum distances to the chest wall were found along the
anterior of the PA. As the RPA branches out at the posterior
wall of the MPA-LPA, the anterior wall is the natural location
for the placement of the device antenna. Distances to the skin
surface were not found to be statistically significant between
the patient groups (p>0.05).
Regarding the orientation of the PA segments with respect
to each other, the angles between the RPA and LPA did not
change much across the patient groups (Fig. 6). The average
angle between the RPA and LPAwere 68.4±16.4° for Class 2,
74.0±8.9° for Class 3, 76.8±10.5° for Class 4, 76.3±11.2°
for PH, and 81.4±16.8° for Controls. However, there were
some differences between the MPA and LPA angle, with a
large standard deviation observed between the Controls. The
average angle between the MPA and LPA were 29.2±11.2°
for Class 2, 21.3±2.9° for Class 3, 24.0±9.3° for Class 4,
26.6±8.9° for PH, and 21.8±16.9° for Controls. Both angles
were found to be statistically insignificant between patient
groups.
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It is proposed that at least two separate stent sizes
will be required to take into consideration the measure-
ments found in this study. In particular, the length of
the stent is recommended to be 45 mm for the NYHA
Class 4 patients while 40 mm is sufficient for the HF
patients. This is shown in Fig. 7.
Fig. 3 Measurements and analysis of the pulmonary artery segments for
each group of patients based on the centreline. a Lengths of MPA,
Bifurcation, LPA and RPA; b length from MPA to LPA; c average
height of the pulmonary sinuses; d average minimum distance of
closest MPA point to the chest wall
Fig. 4 Average cross sectional area of PA segments along the centreline normalised to body height, in cm2/m (top row) and average values of the area-
derived diameter (bottom row)—left to right: MPA, LPA and RPA. The x-axis in all graphs is the normalised length of the pulmonary artery sections
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Discussion
The data presented in this paper was analysed to optimise the
design of the SAWPS Device and could be used to select a
range of different stent sizes to fit patient groups with similar
PA morphology and spatial orientation. It will also guide cli-
nicians to determine the most suitable position of the device
within the PA and its branches.
The SAWPS device is a permanent implant and therefore
consideration of the progression of the morphology of the PA
is essential. The first design decision was that the whole
device should rest against the PA wall and become
endothelialised to reduce the risk of thromboembolism. An
alternative approach has been taken by CardioMems [9]
where a PA pressure sensor was placed in the LPA without
regard to its position with respect to the vessel wall. They
recorded no adverse events related to thromboembolism with-
in the duration of the trial. The data on MPA area-derived
diameter shows that a stent diameter chosen to fit a normal
patient (c. 25 mm+oversizing) could be inadequate if the
patient developed HF (c. 30 mm at III or IV) or PH (c.
35 mm). A self-expanding Nitinol design with a resting
Fig. 5 aMinimum distance to chest skin along MPA (from PV to RPA start) and LPA (from end of RPA to first LPA branch); b point on the centreline
closest to the chest wall and corresponding chest wall point; the RPA and partially the LPA are hidden due to the aorta
Fig. 6 Angle between the segments after the bifurcation: a RPA and LPA, bMPA and LPA
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diameter of 40–45 mm with a radial strength sufficient to
anchor the device during endothelialisation (6–12 weeks),
but not too high to avoid the risks of stimulating exaggerated
neointimal growth, vessel erosion and aneurysm formation
[22, 23] would be ideal.
The longitudinal aspect and low profile of the device are
well suited to lying against the inner wall of a tube. The an-
tenna is flexible and will naturally rest against the wall if the
vessel has a concave longitudinal surface, which is the case on
the anterior surface of the MPA. The distal part of the antenna
will be further held against the wall by the flowing blood; the
proximal part needs to be held against the wall during
endothelialisation to avoid generating vortices in the blood
flow and the risk of emboli.
The stent can extend into the LPA or RPA—but given the
significant discrepancy in size between the main PA and its
branches it must be designed with different segmental radial
sizes and strengths. The sharp angulation of the RPA means
that the LPA is an easier choice for placement of the distal part
of the device. The anterior wall from the MPA into the LPA is
essentially a single concave surface. Extension across the bi-
furcation is permissible if the stent struts are spaced widely
enough (open-cell design) to allow for unobstructed flow into
the partially jailed right branch, as shown in Fig. 7. The length
of the stent will need to be customised; the data suggests that a
40 mm stent length may not be sufficient for extension across
the bifurcation in NYHA Class 4 HF patients and perhaps
lengthening to 45 mm is necessary. Similarly, strut thickness
needs to be minimised to reduce the risk of thrombus forma-
tion and/or flow alteration in the event of incomplete
endothelialisation. Finally, the ideal stent would have a low
profile that enables it to be delivered via a reasonably-sized
highly-trackable sheath. Good imaging and good rotational
registration between the catheter handle and tip will be neces-
sary for optimal deployment.
Given the importance of placing the antenna as close as
possible to the chest wall to enhance signal transmission, the
antenna should be radiopaque to allow for optimal positioning
and orientation within the pulmonary artery during implanta-
tion. For better wave propagation and RF signal noise
reduction, positioning the device in the MPA segment is pref-
erable. This is due to the fact that the MPA is the nearest
segment to the sternum and chest wall and is not covered by
other anatomical structures (the RPA segment is partially be-
hind the ascending aorta). With optimal placement of the im-
plant, there will be much greater tolerance on the optimal
location of the ID antenna on the chest wall and more freedom
to make an ergonomically-driven decision on placing the ex-
ternal antenna—for instance, within clothing.
At a recent initial preclinical test, an implantable SAWPS
was delivered by an 18 F catheter into the main PA of a 75-kg
swine via the femoral vein. The position and orientation of the
device were adjusted using fluoroscopy and transoesophageal
echocardiography before final deployment. The implanted
sensor was interrogated and the signal quality was evaluated.
The transmitting power and the received signal quality con-
firmed the previously measured performance of the implant-
able antenna with respect to the main PA orientation. The
sensor orientation was observed to be parallel to the chest wall
and the implantation depth was measured at 5 cm using the
acquired images. The implanted sensor was interrogated for
30 min and the received signal was monitored in real time.
The received signal quality was consistently good for about
25 min but started to deteriorate afterwards before the signal
was completely lost at 30 min. The autopsy confirmed that
migration of the implant into the LPAwas the cause of signal
loss. The migration occurred because the stent was under-
sized; the signal loss was due to the non-ideal orientation
and depth of the LPAwith respect to the chest wall in swine.
Conclusion
Analysis has been performed on PA orientation and morphol-
ogy from four patient groups and a control group and results
show variance in PA segment lengths that will affect device
placement. Initial preclinical tests confirmed the need for cor-
rect sizing and positioning of the device to ensure good re-
ceived signal quality. These measurements will aid in stent
Fig. 7 Virtual deployment of the
proposed stent in the PA of a a
NYHAClass 4 HF patient and b a
PH patient
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design for future iterations of the SAWPS device and will
ensure better management of patients with heart disease.
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